Skip to contentClarengateINTELLIGENCE
Coverage & freshness About Clarengate
Companies/SC512315

Roslin Cell Therapies Limited

Research and experimental development on biotechnology · Edinburgh

ActiveUnited KingdomIncorporated 2015Private Limited Company
Register Ask analyst

Documents & history

Available account evidence and business events. This is not a complete filing history or document library.

No electronic account filings

No extracted electronic accounts are available in our records.

Registered details

SC512315
Status
Active
Type
Private Limited Company
Incorporated
2015-08-04
Jurisdiction
—
Registered office
NINE EDINBURGH BIOQUARTER, 9 LITTLE FRANCE ROAD, EDINBURGH, EH16 4UX, SCOTLAND

Classification

1 SIC codes
72110

Capital & company events

Reconstructed equity rounds and matched research funding.

Equity fundraising

0 SH01-derived rounds

No reconstructed allotment rounds.

Research and innovation

8 matched grants
COVID-19 continuity grant for Project: 104520Lead
Innovate UK · Feasibility Studies · 2020-06-01 – 2021-03-31
£162,903
awarded
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategyLead
Innovate UK · Collaborative R&D · 2018-10-01 – 2021-12-31 · with 1 other participant
£750,270
awarded
Roslin Cell Therapies Limitedlead£750,270
Reprocell Europe Limited£119,469
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategyLead
ISCF · Collaborative R&D · 2018-09-30 – 2021-12-31 · with 1 other participant
£869,739
whole project
Roslin Cell Therapies LimitedleadReprocell Europe Limited
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategy
ISCF · Collaborative R&D · 2018-09-30 – 2021-12-31 · with 1 other participant
£869,739
whole project
Roslin Cell Therapies LimitedleadReprocell Europe Limited
Northern Alliance Advanced Therapies Treatment Centre
Innovate UK · Collaborative R&D · 2018-03-01 – 2022-03-31 · with 19 other participants
£34,192
awarded
The Newcastle upon Tyne Hospitals NHS Foundation Trustlead£1,623,506
Autolus Limited£1,287,315
Newcastle University£701,226
Trakcel Limited£610,406
Asymptote Limited£574,792
Scottish National Blood Transfusion Service£470,116
The Leeds Teaching Hospitals NHS Trust£459,749
Lothian Health Board£308,221
University of Edinburgh£276,428
NHS Blood and Transplant£261,849
NHS Greater Glasgow and Clyde£227,470
Alcyomics Limited£212,574
Datatrial Limited£155,760
Health Innovation North East And North Cumbria Limited£133,848
Thermo Electron Limited£123,055
World Courier Logistics (UK) Limited£64,311
Roslin Cell Therapies Limited£34,192
Cell Medica Limited£19,511
Chiesi Limited£0
Miltenyi Biotec Limited£0
Northern Alliance Advanced Therapies Treatment Centre
ISCF · Collaborative R&D · 2018-03-01 – 2022-03-30 · with 19 other participants
£7,544,329
whole project
The Newcastle Upon Tyne Hospitals NHS Foundation TrustleadAlcyomics LimitedAsymptote LimitedAutolus LimitedCell Medica LimitedChiesi LimitedDatatrial LimitedHealth Innovation North East And North Cumbria LimitedLothian Health BoardMiltenyi Biotec LimitedNewcastle UniversityNHS Blood And TransplantNHS Greater Glasgow And ClydeRoslin Cell Therapies LimitedScottish National Blood Transfusion ServiceThe Leeds Teaching Hospitals NHS TrustThermo Electron LimitedTrakcel LimitedUniversity Of EdinburghWorld Courier Logistics (UK) Limited
Multi-donor allogeneic human retinal progenitor cell therapy (hRPC) 4sight
Innovate UK · Collaborative R&D · 2018-02-01 – 2020-04-30 · with 3 other participants
£642,516
awarded
Roslin Cell Therapies Limited£642,516
Cell Therapy Catapult Limited£300,140
University College London£298,261
ReNeuron Limitedlead£290,056
Multi-donor allogeneic human retinal progenitor cell therapy (hRPC) 4sight
ISCF · Collaborative R&D · 2018-02-01 – 2020-04-29 · with 3 other participants
£1,530,973
whole project
Reneuron LimitedleadCell Therapy Catapult LimitedRoslin Cell Therapies LimitedUniversity College London